172 related articles for article (PubMed ID: 26914979)
21. Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia.
Cortes J; Thomas D; Rios A; Koller C; O'Brien S; Jeha S; Faderl S; Kantarjian H
Cancer; 2002 Mar; 94(5):1492-9. PubMed ID: 11920506
[TBL] [Abstract][Full Text] [Related]
22. Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma.
Wang ES; Straus DJ; Teruya-Feldstein J; Qin J; Portlock C; Moskowitz C; Goy A; Hedrick E; Zelenetz AD; Noy A
Cancer; 2003 Sep; 98(6):1196-205. PubMed ID: 12973843
[TBL] [Abstract][Full Text] [Related]
23. Long term survival of children with Burkitt lymphoma in Malawi after cyclophosphamide monotherapy.
Kazembe P; Hesseling PB; Griffin BE; Lampert I; Wessels G
Med Pediatr Oncol; 2003 Jan; 40(1):23-5. PubMed ID: 12426682
[TBL] [Abstract][Full Text] [Related]
24. Excellent real-world outcomes of adults with Burkitt lymphoma treated with CODOX-M/IVAC plus or minus rituximab.
Zhu KY; Song KW; Connors JM; Leitch H; Barnett MJ; Ramadan K; Slack GW; Abou Mourad Y; Forrest DL; Hogge DE; Nantel SH; Narayanan S; Nevill TJ; Power MM; Sanford DS; Sutherland HJ; Tucker T; Toze CL; Sehn LH; Broady R; Gerrie AS
Br J Haematol; 2018 Jun; 181(6):782-790. PubMed ID: 29741758
[TBL] [Abstract][Full Text] [Related]
25. Malnutrition and neutropenia in children treated for Burkitt lymphoma in Malawi.
Israëls T; van de Wetering MD; Hesseling P; van Geloven N; Caron HN; Molyneux EM
Pediatr Blood Cancer; 2009 Jul; 53(1):47-52. PubMed ID: 19338050
[TBL] [Abstract][Full Text] [Related]
26. Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial.
Oki Y; Ewer MS; Lenihan DJ; Fisch MJ; Hagemeister FB; Fanale M; Romaguera J; Pro B; Fowler N; Younes A; Astrow AB; Huang X; Kwak LW; Samaniego F; McLaughlin P; Neelapu SS; Wang M; Fayad LE; Durand JB; Rodriguez MA
Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):152-8. PubMed ID: 25445468
[TBL] [Abstract][Full Text] [Related]
27. Factors influencing survival among Kenyan children diagnosed with endemic Burkitt lymphoma between 2003 and 2011: A historical cohort study.
Buckle G; Maranda L; Skiles J; Ong'echa JM; Foley J; Epstein M; Vik TA; Schroeder A; Lemberger J; Rosmarin A; Remick SC; Bailey JA; Vulule J; Otieno JA; Moormann AM
Int J Cancer; 2016 Sep; 139(6):1231-40. PubMed ID: 27136063
[TBL] [Abstract][Full Text] [Related]
28. A 5-drug regimen maximizing the dose of cyclophosphamide is effective therapy for adult Burkitt or Burkitt-like lymphomas.
Kujawski LA; Longo WL; Williams EC; Turman NJ; Brandt N; Mosher DF; Eickhoff JC; Kahl BS
Cancer Invest; 2007 Mar; 25(2):87-93. PubMed ID: 17453819
[TBL] [Abstract][Full Text] [Related]
29. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.
Robak T; Jin J; Pylypenko H; Verhoef G; Siritanaratkul N; Drach J; Raderer M; Mayer J; Pereira J; Tumyan G; Okamoto R; Nakahara S; Hu P; Appiani C; Nemat S; Cavalli F;
Lancet Oncol; 2018 Nov; 19(11):1449-1458. PubMed ID: 30348538
[TBL] [Abstract][Full Text] [Related]
30. Dissecting heterogeneous outcomes for paediatric Burkitt lymphoma in Malawi after anthracycline-based treatment.
Westmoreland KD; El-Mallawany NK; Kazembe P; Stanley CC; Gopal S
Br J Haematol; 2018 Jun; 181(6):853-854. PubMed ID: 28714257
[No Abstract] [Full Text] [Related]
31. Estimation of the relationship between caspase-3 expression and clinical outcome of Burkitt's and Burkitt-like lymphoma.
Nomura Y; Yoshida S; Karube K; Takeshita M; Hirose S; Nakamura S; Yoshino T; Kikuchi M; Ohshima K
Cancer Sci; 2008 Aug; 99(8):1564-9. PubMed ID: 18754867
[TBL] [Abstract][Full Text] [Related]
32. CHOP chemotherapy with preemptive granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma: a dose-intensity analysis.
Jacobson JO; Grossbard M; Shulman LN; Neuberg D
Clin Lymphoma; 2000 Dec; 1(3):211-7; discussion 218. PubMed ID: 11707832
[TBL] [Abstract][Full Text] [Related]
33. The effect of optimal treatment on elderly patients with aggressive non-Hodgkin's lymphoma: more patients treated with unaffected response rates.
Peters FP; Fickers MM; Erdkamp FL; Wals J; Wils JA; Schouten HC
Ann Hematol; 2001 Jul; 80(7):406-10. PubMed ID: 11529466
[TBL] [Abstract][Full Text] [Related]
34. [Clinical and Prognostic analysis of 43 Children with Mature B-cell Non-Hodgkin's Lymphoma/Acute Lymphoblastic Leukemia].
Guo J; Zhu YP; Gao J; Li Q; Jia CS; Zhou CY; Guo X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Feb; 24(1):72-9. PubMed ID: 26913397
[TBL] [Abstract][Full Text] [Related]
35. Burkitt lymphoma after solid-organ transplant: Treatment and outcomes in the paediatric PTLD collaborative.
Afify Z; Orjuela-Grimm M; Smith CM; Dalal M; Ford JB; Pillai P; Robles JM; Reddy S; McCormack S; Ehrhardt MJ; Ureda T; Alperstein W; Edington H; Miller TP; Rubinstein JD; Kavanaugh M; Bukowinski AJ; Friehling E; Rivers JM; Chisholm KM; Marks LJ; Mason CC
Br J Haematol; 2023 Feb; 200(3):297-305. PubMed ID: 36454546
[TBL] [Abstract][Full Text] [Related]
36. [Gingival Burkitt lymphoma in a hepatitis C-positive renal transplant patient].
Unholzer A; Starz H; Hirschsteiner O; Balda BR
J Dtsch Dermatol Ges; 2005 Jan; 3(1):46-51. PubMed ID: 16353750
[TBL] [Abstract][Full Text] [Related]
37. Short communication: spectrum of non-Hodgkin lymphoma in an urban Ryan White-funded clinic in the established antiretroviral era.
Silverton A; Gunthel C; Adamski M; Mosunjac M; Nguyen ML
AIDS Res Hum Retroviruses; 2014 Jul; 30(7):665-9. PubMed ID: 24707838
[TBL] [Abstract][Full Text] [Related]
38. Outcomes after R-CHOP in patients with newly diagnosed advanced follicular lymphoma: a 10-year follow-up analysis of the JCOG0203 trial.
Watanabe T; Tobinai K; Wakabayashi M; Morishima Y; Kobayashi H; Kinoshita T; Suzuki T; Yamaguchi M; Ando K; Ogura M; Taniwaki M; Uike N; Yoshino T; Nawano S; Terauchi T; Hotta T; Nagai H; Tsukasaki K;
Lancet Haematol; 2018 Nov; 5(11):e520-e531. PubMed ID: 30389034
[TBL] [Abstract][Full Text] [Related]
39. Dose-adjusted EPOCH-R for Burkitt lymphoma.
Hoelzer D
Clin Adv Hematol Oncol; 2014 Nov; 12(11):777-9. PubMed ID: 25674718
[No Abstract] [Full Text] [Related]
40. Addition of bortezomib to standard dose chop chemotherapy improves response and survival in relapsed mantle cell lymphoma.
Furtado M; Johnson R; Kruger A; Turner D; Rule S
Br J Haematol; 2015 Jan; 168(1):55-62. PubMed ID: 25146720
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
